Jason Zemansky
Stock Analyst at Bank of America Securities
(4.84)
# 383
Out of 4,693 analysts
449
Total ratings
61.4%
Success rate
23.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintained: Hold | $85 | $71.40 | +19.05% | 50 | Aug 31, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $30 → $31 | $12.89 | +140.50% | 41 | Aug 13, 2026 | |
| RCUS Arcus Biosciences | Reiterated: Hold | $29 | $29.71 | -2.39% | 38 | Aug 11, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $101 → $104 | $76.57 | +35.82% | 37 | Aug 11, 2026 | |
| KROS Keros Therapeutics | Reiterated: Hold | $20 → $17 | $11.07 | +53.57% | 17 | Aug 11, 2026 | |
| LYEL Lyell Immunopharma | Reiterated: Sell | $12 | $14.53 | -17.38% | 12 | Aug 11, 2026 | |
| TYRA Tyra Biosciences | Reiterated: Buy | $42 → $39 | $25.30 | +54.15% | 16 | Aug 11, 2026 | |
| INSM Insmed | Maintained: Buy | $209 → $214 | $121.51 | +76.12% | 51 | Aug 7, 2026 | |
| LGND Ligand Pharmaceuticals | Reiterated: Buy | n/a | $284.27 | - | 10 | Aug 7, 2026 | |
| TVTX Travere Therapeutics | Maintained: Buy | $64 → $71 | $65.71 | +8.05% | 30 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 → $26 | $20.10 | +29.35% | 35 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.73 | +168.10% | 19 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $553 → $543 | $538.71 | +0.80% | 27 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $215 → $219 | $216.04 | +1.37% | 15 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $2.38 | +152.10% | 5 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $2.92 | +173.97% | 13 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 → $32 | $10.88 | +194.12% | 3 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $0.9575 | +631.07% | 19 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $64.84 | n/a | 2 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $15 → $12 | $3.56 | n/a | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $1 | $3.92 | n/a | 3 | Dec 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $14.36 | n/a | 2 | Nov 17, 2023 |
Cytokinetics
Aug 31, 2026
Maintained: Hold
Price Target: $85
Current: $71.40
Upside: +19.05%
Kura Oncology
Aug 13, 2026
Reiterated: Buy
Price Target: $30 → $31
Current: $12.89
Upside: +140.50%
Arcus Biosciences
Aug 11, 2026
Reiterated: Hold
Price Target: $29
Current: $29.71
Upside: -2.39%
BridgeBio Pharma
Aug 11, 2026
Reiterated: Buy
Price Target: $101 → $104
Current: $76.57
Upside: +35.82%
Keros Therapeutics
Aug 11, 2026
Reiterated: Hold
Price Target: $20 → $17
Current: $11.07
Upside: +53.57%
Lyell Immunopharma
Aug 11, 2026
Reiterated: Sell
Price Target: $12
Current: $14.53
Upside: -17.38%
Tyra Biosciences
Aug 11, 2026
Reiterated: Buy
Price Target: $42 → $39
Current: $25.30
Upside: +54.15%
Insmed
Aug 7, 2026
Maintained: Buy
Price Target: $209 → $214
Current: $121.51
Upside: +76.12%
Ligand Pharmaceuticals
Aug 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $284.27
Upside: -
Travere Therapeutics
Aug 5, 2026
Maintained: Buy
Price Target: $64 → $71
Current: $65.71
Upside: +8.05%
Aug 5, 2026
Maintained: Buy
Price Target: $29 → $26
Current: $20.10
Upside: +29.35%
Aug 3, 2026
Maintained: Buy
Price Target: $10
Current: $3.73
Upside: +168.10%
Jul 30, 2026
Reiterated: Hold
Price Target: $553 → $543
Current: $538.71
Upside: +0.80%
Jul 29, 2026
Reiterated: Hold
Price Target: $215 → $219
Current: $216.04
Upside: +1.37%
Jul 27, 2026
Maintained: Buy
Price Target: $6
Current: $2.38
Upside: +152.10%
Jun 11, 2026
Maintained: Buy
Price Target: $8
Current: $2.92
Upside: +173.97%
Jun 3, 2026
Reiterated: Buy
Price Target: $34 → $32
Current: $10.88
Upside: +194.12%
Feb 17, 2026
Reiterated: Buy
Price Target: $7
Current: $0.9575
Upside: +631.07%
Oct 30, 2024
Maintained: Buy
Price Target: n/a
Current: $64.84
Upside: n/a
Mar 28, 2024
Reiterated: Sell
Price Target: $15 → $12
Current: $3.56
Upside: n/a
Dec 26, 2023
Maintained: Sell
Price Target: $1
Current: $3.92
Upside: n/a
Nov 17, 2023
Rated: Hold
Price Target: n/a
Current: $14.36
Upside: n/a